Literature DB >> 27631600

High Vitamin D-Binding Protein Concentration, Low Albumin, and Mode of Remission Predict Relapse in Crohn's Disease.

Simon Ghaly1, Kevin Murray, Angela Baird, Katherine Martin, Ruth Prosser, Justine Mill, Lisa A Simms, Prue H Hart, Graham Radford-Smith, Peter A Bampton, Ian C Lawrance.   

Abstract

BACKGROUND: Vitamin D (25(OH)D) deficiency occurs in active Crohn's disease (CD) and may be secondary to reduced sunlight exposure and oral intake. Vitamin D-binding protein (VDBP) levels, however, fluctuate less with season and sunlight. The aim, therefore, was to examine patients with CD in remission and determine any associations between VDBP, serum 25(OH)D, and the calculated free 25(OH)D concentrations with the risk of disease flare.
METHODS: Subjects were identified from prospectively maintained inflammatory bowel disease databases at 3 teaching hospitals in Australia. Patients were in steroid-free clinical remission at the time of blood draw and were followed for at least 12 months. Total and epimer-25(OH)D3, VDBP concentrations, and genotypes were determined.
RESULTS: A total of 309 patients with CD (46% men) met the inclusion criteria. A disease flare occurred in 100 (32.4%). Serum 25(OH)D3 was deficient (<50 nmol/L) in 36 (12%) and insufficient (50-75 nmol/L) in 107 (35%) patients. Total, free, and epimer-25(OH)D3 serum levels did not predict disease flare. Higher VDBP concentrations, however, significantly correlated with increased risk of disease flare (hazard ratio 1.2, 95% CI, 1.0-1.5). On multivariate analysis, VDBP concentration, low albumin, and medication-induced remission were significantly more associated with disease flare. VDBP genotypes were significantly associated with 25(OH)D and VDBP concentrations but not disease flare.
CONCLUSIONS: Vitamin D deficiency was uncommon in our patients with CD in remission, and serum 25(OH)D3 did not predict disease flare, whereas higher VDBP concentrations were significantly associated with disease flare. Further investigations to explore the possible mechanisms for this association are warranted.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27631600     DOI: 10.1097/MIB.0000000000000894

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  11 in total

1.  Impact of Etanercept on Vitamin D Status and Vitamin D-binding Protein in Bio-naïve Patients with Psoriasis.

Authors:  Maria Siekkeri Vandikas; Kerstin Landin-Wilhelmsen; Sam Polesie; Martin Gillstedt; Amra Osmancevic
Journal:  Acta Derm Venereol       Date:  2021-11-24       Impact factor: 3.875

2.  Functional Molecular Network Analysis Enables Prediction of Response to Vedolizumab Therapy in Anti-TNF Refractory IBD Patients.

Authors:  Matthias Breidert; Pierre Eftekhari; François Louis; Claudia Rotoiu; Timo Rath; Markus F Neurath; Raja Atreya
Journal:  Crohns Colitis 360       Date:  2020-05-24

Review 3.  Crohn's disease.

Authors:  Giulia Roda; Siew Chien Ng; Paulo Gustavo Kotze; Marjorie Argollo; Remo Panaccione; Antonino Spinelli; Arthur Kaser; Laurent Peyrin-Biroulet; Silvio Danese
Journal:  Nat Rev Dis Primers       Date:  2020-04-02       Impact factor: 52.329

4.  Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn's Disease.

Authors:  Remo Panaccione; A Hillary Steinhart; Brian Bressler; Reena Khanna; John K Marshall; Laura Targownik; Waqqas Afif; Alain Bitton; Mark Borgaonkar; Usha Chauhan; Brendan Halloran; Jennifer Jones; Erin Kennedy; Grigorios I Leontiadis; Edward V Loftus; Jonathan Meddings; Paul Moayyedi; Sanjay Murthy; Sophie Plamondon; Greg Rosenfeld; David Schwartz; Cynthia H Seow; Chadwick Williams; Charles N Bernstein
Journal:  J Can Assoc Gastroenterol       Date:  2018-07-10

5.  High Dose Vitamin D supplementation alters faecal microbiome and predisposes mice to more severe colitis.

Authors:  Simon Ghaly; Nadeem O Kaakoush; Frances Lloyd; Terence McGonigle; Danny Mok; Angela Baird; Borut Klopcic; Lavinia Gordon; Shelley Gorman; Cynthia Forest; Roger Bouillon; Ian C Lawrance; Prue H Hart
Journal:  Sci Rep       Date:  2018-07-31       Impact factor: 4.379

6.  Multiple genome analyses reveal key genes in Vitamin C and Vitamin D synthesis and transport pathways are shared.

Authors:  Wei Dong; Cheng Tian; Yan Jiao; Savannah Blackwell; Ge Lou; Arnold Postlethwaite; Weikuan Gu; Dianjun Sun
Journal:  Sci Rep       Date:  2019-11-14       Impact factor: 4.379

7.  Measuring Vitamin D Status in Chronic Inflammatory Disorders: How does Chronic Inflammation Affect the Reliability of Vitamin D Metabolites in Patients with IBD?

Authors:  Aysegül Aksan; Dilem Tugal; Nathalena Hein; Katharina Boettger; Yurani Caicedo-Zea; Ina Diehl; Claudia Schumann; Franz-Paul Armbruster; Jürgen Stein
Journal:  J Clin Med       Date:  2020-02-17       Impact factor: 4.241

8.  Vitamin D-Binding Protein and the Free Hormone Hypothesis for Vitamin D in Bio-Naïve Patients with Psoriasis.

Authors:  Maria Siekkeri Vandikas; Kerstin Landin-Wilhelmsen; Martin Gillstedt; Amra Osmancevic
Journal:  Int J Mol Sci       Date:  2022-01-24       Impact factor: 5.923

Review 9.  Clinical Practice Guideline for the Medical Management of Perianal Fistulizing Crohn's Disease: The Toronto Consensus.

Authors:  A Hillary Steinhart; Remo Panaccione; Laura Targownik; Brian Bressler; Reena Khanna; John K Marshall; Waqqas Afif; Charles N Bernstein; Alain Bitton; Mark Borgaonkar; Usha Chauhan; Brendan Halloran; Jennifer Jones; Erin Kennedy; Grigorios I Leontiadis; Edward V Loftus; Jonathan Meddings; Paul Moayyedi; Sanjay Murthy; Sophie Plamondon; Greg Rosenfeld; David Schwartz; Cynthia H Seow; Chadwick Williams
Journal:  J Can Assoc Gastroenterol       Date:  2018-09-14

10.  Vitamin D metabolites are lower with active Crohn's disease and spontaneously recover with development of remission.

Authors:  Craig Haifer; Ian C Lawrance; Jacqueline R Center; Michael W Clarke; Prue H Hart; John A Eisman; Robyn Lucas; Simon Ghaly
Journal:  Therap Adv Gastroenterol       Date:  2019-07-26       Impact factor: 4.409

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.